• Monoaminergic signaling (dopamine, serotonin, norepinephrine) is central to schizophrenia and brain function, framed as chemical mediators with brain distribution patterns and metabolism across multiple studies. [3], [6], [12], [13], [14], [16], [19], [20]

• Genetic and polygenic frameworks for schizophrenia emerged, positing inherited architectures such as schizotypy and schizoid traits as core to disease risk. [7], [8], [10], [15]

• Biologic basis research integrates clinical psychiatry with neuropsychology, emphasizing how brain biology informs diagnosis and subclassification. [4], [17], [18]

• Biochemical measurement methodologies in psychiatry advanced via assays for serotonin, dopamine, norepinephrine, and related enzymes, enabling biomarker discovery. [9], [13], [14], [20]

• Dopamine metabolism and related transformations in schizophrenia were explored, including dopamine-to-metabolite conversions and methylation pathways. [3], [12], [16]